The economics of moonshots: Value in rare disease drug development
- PMID: 35334152
- PMCID: PMC9010265
- DOI: 10.1111/cts.13270
The economics of moonshots: Value in rare disease drug development
Conflict of interest statement
The authors declared no competing interests for this work.
References
-
- Richter T, Nestler‐Parr S, Babela R, et al. Rare disease terminology and definitions—a systematic global review: report of the ISPOR rare disease special interest group. Value Health. 2015;18:906‐914. - PubMed
-
- Bagley N, Berger B, Chandra A, Garthwaite C, Stern AD. The Orphan Drug Act at 35: observations and an outlook for the twenty‐first century. Innov Policy Econ. 2019;19:97‐137.
-
- Sarpatwari A, Beall RF, Abdurrob A, He M, Kesselheim AS. Evaluating the impact of the Orphan Drug Act’s seven‐year market exclusivity period. Health Aff. 2018;37:732‐737. - PubMed
-
- Nabhan C, Phillips EG Jr, Feinberg BA. Orphan cancer drugs in the era of precision medicine. JAMA Oncol. 2018;4:1481‐1482. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
